Abstract

Stroke is a leading cause of morbidity and mortality in the United States. Whether hemorrhagic or ischemic, stroke leads to severe long-term disability. Prior to the mid-1990s, the treatment offered to a patient who presented with an acute stroke was mainly limited to antiplatelets. The lack of adequate treatment, in particular, one without reperfusion contributed to the disability that ensued. There have been many advances in stroke care within the past two decades, especially with the acute management of ischemic stroke. Even with these advances, it is quite alarming that only a fraction of patients receives acute stroke treatment. Numerous trials were conducted to broaden treatment eligibility in hopes that more patients can be treated acutely and safely. These trials have tested both the time window for IV tPA and endovascular therapy (EVT). Acute stroke management is moving from a universal time window approach to a concept of tissue preservation. Specifically, preserving cerebral blood flow, the penumbra, and reducing the risk of a second event. This movement is being executed through the use of multimodal CT and MRI, as well as individualizing treatment to our patients. Minimizing the initial effect of stroke changes the outcome and leads to an increased likelihood of functional independence. In this review, we discuss the recent updates of acute ischemic stroke management in regards to mechanical thrombectomy as well as thrombolytics including tenecteplase.

Highlights

  • The term stroke was originally referred to as “apoplexy,” after its discovery by Hippocrates over 2500 years ago

  • Such community. trials will continue to influence and impact the care we Thrombolytic therapy became the standard of care for acute ischemic stroke after the publication of the Tissue Plasminogen Activator for Acute Ischemic Stroke conducted by the National Institute of Neurologic Disorders and Stroke (NINDS tPA trial)

  • Though Computed tomography (CT) is useful in disqualifying patients for thrombolytics by identifying hemorrhage or subacute ischemic strokes, more advanced imaging modalities such as MRI and perfusion studies have demonstrated efficacy in identifying patients that are eligible for treatment outside the traditional treatment window, especially those without a clear last known well time [5,6,7,8]

Read more

Summary

Alteplase

Advanced imaging modalities can be used to evaluate the evolution of an ischemic stroke and assess the safety of thrombolytic therapy in a method that is not solely based on time but based on the concept of a “tissue clock” [6,7,9] Using this concept, WAKE UP and MR WITNESS trials demonstrated both the efficacy and safety of treating patients with tPA presenting greater than 4.5 hours of last known well by using MRI. ECASS IV and EXTEND enrolled patients with a last known well time between 4.5 to 9.0 hours who were not eligible for mechanical thrombectomy, with a perfusion to diffusion mismatch ratio of 1.2 or greater [15,16] Both trials demonstrated a significant rate of symptomatic hemorrhage with IV tPA, but the rates were similar to previous trials such as the NINDS tPA trial and ECASS III [3,4,15,16]. This trial was terminated early, no definitive conclusion can be made

Tenecteplase
Study Design
Endovascular
Findings
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call